[go: up one dir, main page]

CO5280045A1 - Nueva composicion - Google Patents

Nueva composicion

Info

Publication number
CO5280045A1
CO5280045A1 CO00066605A CO00066605A CO5280045A1 CO 5280045 A1 CO5280045 A1 CO 5280045A1 CO 00066605 A CO00066605 A CO 00066605A CO 00066605 A CO00066605 A CO 00066605A CO 5280045 A1 CO5280045 A1 CO 5280045A1
Authority
CO
Colombia
Prior art keywords
mpl
antigen
vaccine composition
new composition
preferential stimulator
Prior art date
Application number
CO00066605A
Other languages
English (en)
Inventor
Anne Cecile Wettendorf Martine
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO5280045A1 publication Critical patent/CO5280045A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09C—RECLAMATION OF CONTAMINATED SOIL
    • B09C1/00—Reclamation of contaminated soil
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D3/00—Improving or preserving soil or rock, e.g. preserving permafrost soil
    • E02D3/11—Improving or preserving soil or rock, e.g. preserving permafrost soil by thermal, electrical or electro-chemical means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Soil Sciences (AREA)
  • Molecular Biology (AREA)
  • Structural Engineering (AREA)
  • Environmental & Geological Engineering (AREA)
  • Oncology (AREA)
  • Paleontology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Agronomy & Crop Science (AREA)
  • Biotechnology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Mining & Mineral Resources (AREA)
  • Biochemistry (AREA)
  • Civil Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Una composición de vacuna que comprende:(a) un antígeno de virus del herpes simple (HSV), y(b) un antígeno de virus del papiloma humano (HPV)en combinación con un coadyuvante que es un estimuladorpreferente de la respuesta celular TH1. Una composición de vacuna según las reivindicaciones 1 ó 2, en la que el estimulador preferencial de la respuesta celular TH1 se selecciona del grupo de coadyuvantes que comprende: 3D-MPL, 3D-MPL, siendo el tamaño de partícula de 3D-MPL preferiblemente de aproximadamente igual o inferior a 100 nm, QS21, una mezcla de QS21 y colesterol y un oligonucleótido CpG.
CO00066605A 1999-09-07 2000-09-05 Nueva composicion CO5280045A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9921146A GB9921146D0 (en) 1999-09-07 1999-09-07 Novel composition

Publications (1)

Publication Number Publication Date
CO5280045A1 true CO5280045A1 (es) 2003-05-30

Family

ID=10860520

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00066605A CO5280045A1 (es) 1999-09-07 2000-09-05 Nueva composicion

Country Status (33)

Country Link
US (3) US6936255B1 (es)
EP (3) EP1769806A3 (es)
JP (2) JP4689910B2 (es)
KR (2) KR100594668B1 (es)
CN (2) CN1325117C (es)
AR (1) AR025502A1 (es)
AT (2) ATE312624T1 (es)
AU (1) AU766494B2 (es)
BR (1) BR0014171A (es)
CA (2) CA2384064C (es)
CO (1) CO5280045A1 (es)
CY (2) CY1107457T1 (es)
CZ (2) CZ302811B6 (es)
DE (2) DE60027029T2 (es)
DK (2) DK1210113T3 (es)
ES (2) ES2253636T3 (es)
GB (1) GB9921146D0 (es)
GC (1) GC0000201A (es)
HK (1) HK1048435B (es)
HU (2) HU229099B1 (es)
IL (3) IL158107A0 (es)
MX (1) MXPA02002484A (es)
MY (2) MY142842A (es)
NO (3) NO332800B1 (es)
NZ (2) NZ527560A (es)
PL (2) PL201264B1 (es)
PT (1) PT1210113E (es)
SG (1) SG110072A1 (es)
SI (2) SI1410805T1 (es)
TR (1) TR200200607T2 (es)
TW (1) TWI258374B (es)
WO (1) WO2001017551A2 (es)
ZA (2) ZA200306402B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
CN101926993B (zh) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP1243655B1 (en) * 2001-03-23 2007-02-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modified HPV E6 and E7 genes and proteins useful for vaccination
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE60326449D1 (de) † 2002-05-17 2009-04-16 Univ Cape Town Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel
CN1650012A (zh) 2002-07-24 2005-08-03 英特塞尔股份公司 来自致病病毒的备选阅读框所编码的抗原
JP2006504687A (ja) 2002-09-13 2006-02-09 インターツェル・アクチェンゲゼルシャフト Ｃ型肝炎ウイルスペプチドの単離方法
DK2241325T3 (da) 2002-10-29 2012-04-10 Coley Pharm Group Inc Anvendelse af CPG-oligonukleotider til behandling af Hepatitis Cvirusinfektion
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
CN100418577C (zh) * 2002-12-20 2008-09-17 葛兰素史密丝克莱恩生物有限公司 Hpv-16和hpv-18l1vlp疫苗
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
WO2004056389A1 (en) * 2002-12-20 2004-07-08 Glaxosmithkline Biologicals Sa Hpv-16 and -18 l1 vlp vaccine
CN100355453C (zh) * 2003-03-24 2007-12-19 英特塞尔股份公司 改进的疫苗
EP1608402B1 (en) 2003-03-24 2010-10-20 Intercell AG Improved vaccines
RU2420313C2 (ru) * 2004-06-16 2011-06-10 ГлаксоСмитКлайн Байолоджикалз с.а. Вакцина против вирусов папилломы человека hpv 16 и hpv 18 и по меньшей мере еще одного типа hpv, выбранного из hpv 31, 45 или 52
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
EA012212B1 (ru) * 2005-02-16 2009-08-28 Новартис Вэксинес Энд Дайэгностикс, Инк. Адъювантная композиция, содержащая фосфат алюминия и 3d-mpl
JP4182074B2 (ja) 2005-03-03 2008-11-19 ファナック株式会社 ハンド及びハンドリングロボット
PE20061428A1 (es) * 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
CA2606092A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
WO2006114273A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
US7790203B2 (en) * 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
RU2488407C2 (ru) 2005-12-29 2013-07-27 Берингер Ингельхайм Ветмедика, Инк. Поливалентные иммуногенные композиции pcv2 и способы получения таких композиций
DK2371383T3 (en) 2005-12-29 2015-11-30 Boehringer Ingelheim Vetmed Use of a PCV2 immunogenic composition for reduction of clinical symptoms in pigs
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
ES2657392T3 (es) 2006-09-26 2018-03-05 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
JP2010520874A (ja) 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
RU2471807C2 (ru) * 2007-06-26 2013-01-10 Джапан Хелт Сайенсес Фаундейшн Вакцинный антиген, способный индуцировать перекрестно реагирующее и нейтрализующее антитело против папилломавируса человека с высоким риском
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
EP2298344B1 (en) 2008-06-04 2016-08-17 The Chemo-Sero-Therapeutic Research Institute Use of inactivated japanese encephalitis virus particle as adjuvant
HRP20141063T1 (hr) * 2008-07-31 2015-01-02 Glaxosmithkline Biologicals S.A. Cjepivo protiv hpv
ES2732815T3 (es) 2009-05-22 2019-11-26 Genocea Biosciences Inc Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
CN102215861B (zh) * 2009-06-19 2014-10-08 艾金株式会社 宫颈癌疫苗
KR20120098580A (ko) * 2009-06-25 2012-09-05 글락소스미스클라인 바이오로지칼즈 에스.에이. 인간 파필로마바이러스（ｈｐｖ） 단백질 작제물 및 ｈｐｖ 질환을 예방하기 위한 이의 용도
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
CN103025351B (zh) * 2010-05-28 2016-08-24 佐蒂斯比利时股份有限公司 包含胆固醇和作为唯一的佐剂-载剂分子的cpg的疫苗
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
BR112013004594B1 (pt) * 2010-08-27 2020-07-28 Intervet International B. V. método para a determinação de um conteúdo de antígeno
CN102008721A (zh) * 2010-11-16 2011-04-13 浙江大学 一种hpv多肽/dc混合疫苗及其制备
CA2856697A1 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN102210858B (zh) * 2011-05-18 2013-05-08 北京科兴生物制品有限公司 一种肠道病毒71型与甲型肝炎联合疫苗
JP6050811B2 (ja) 2011-06-24 2016-12-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アルミニウムアジュバントを含むｈｐｖワクチン製剤およびその産生方法
JP6109165B2 (ja) * 2011-07-01 2017-04-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヘルペスウイルスワクチンおよび使用方法
AU2012340712B2 (en) 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
RS58868B1 (sr) 2012-02-07 2019-08-30 Infectious Disease Res Inst Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
AU2017305176B2 (en) 2016-08-01 2021-05-27 The Wistar Institute Of Anatomy And Biology Compositions and methods of replication deficient adenoviral vectors for vaccine applications
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
CN107987159B (zh) * 2017-11-28 2021-06-22 上海药明生物医药有限公司 一种使用大剂量dna免疫技术免疫动物使血清中抗体滴度提高的方法
GB201821207D0 (en) * 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
CN110576034B (zh) * 2019-10-09 2020-06-30 北京尚华生态环保科技股份公司 一种土壤原位修复方法
CN110652980B (zh) * 2019-10-09 2020-06-30 北京尚华生态环保科技股份公司 一种土壤原位修复剂
EP4058581A1 (en) 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
CN114681602B (zh) * 2020-12-25 2023-12-01 中国食品药品检定研究院 一种双价人乳头瘤病毒疫苗
CN114796479A (zh) * 2022-06-02 2022-07-29 金宇保灵生物药品有限公司 一种畜类动物疫苗用水包油包水佐剂及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DE122007000023I1 (de) * 1991-07-19 2007-08-09 Univ Queensland St Lucia Impfsstoff gegen Humanes Papillomavirus (typ 18)
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
JP3958360B2 (ja) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
CA2242200A1 (en) * 1996-01-26 1997-07-31 Innogenetics N.V. Toxoplasma gondii antigen tg20
WO1997028820A1 (en) * 1996-02-09 1997-08-14 Smithkline Beecham Biologicals S.A. Vaccines against varicella zoster virus gene 63 product
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CA2229955C (en) * 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
KR20010041629A (ko) 1998-03-09 2001-05-25 장 스테판느 혼합 백신 조성물
US6500284B1 (en) 1998-06-10 2002-12-31 Suraltech, Inc. Processes for continuously producing fine grained metal compositions and for semi-solid forming of shaped articles
GB9819898D0 (en) 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
CN101926993B (zh) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
EP1150712B1 (en) * 1999-02-05 2008-11-05 Merck & Co., Inc. Human papilloma virus vaccine formulations
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition

Also Published As

Publication number Publication date
MY130084A (en) 2007-05-31
TWI258374B (en) 2006-07-21
EP1210113A2 (en) 2002-06-05
US7220551B2 (en) 2007-05-22
CZ302811B6 (cs) 2011-11-23
HU229099B1 (en) 2013-07-29
JP4689910B2 (ja) 2011-06-01
DK1210113T3 (da) 2006-07-03
AR025502A1 (es) 2002-11-27
IL158107A (en) 2008-11-03
GB9921146D0 (en) 1999-11-10
SG110072A1 (en) 2005-04-28
KR100557665B1 (ko) 2006-03-06
NO331825B1 (no) 2012-04-10
JP2004067696A (ja) 2004-03-04
PL201767B1 (pl) 2009-05-29
CN1618465A (zh) 2005-05-25
TR200200607T2 (tr) 2002-06-21
HUP0202804A3 (en) 2004-08-30
EP1410805A1 (en) 2004-04-21
WO2001017551A3 (en) 2001-09-27
PL354039A1 (en) 2003-12-15
DE60027029D1 (de) 2006-05-18
CY1107457T1 (el) 2012-12-19
HU0303215D0 (en) 2003-11-28
NZ517621A (en) 2003-09-26
ZA200201810B (en) 2004-05-26
PL201264B1 (pl) 2009-03-31
MXPA02002484A (es) 2002-08-28
CZ2002843A3 (cs) 2002-08-14
PT1210113E (pt) 2006-07-31
US7101560B2 (en) 2006-09-05
SI1410805T1 (sl) 2006-04-30
HUP0202804A2 (hu) 2002-12-28
HK1048435A1 (en) 2003-04-04
EP1210113B1 (en) 2006-03-29
KR100594668B1 (ko) 2006-06-30
IL158107A0 (en) 2004-03-28
CA2384064C (en) 2010-06-01
NO20021116D0 (no) 2002-03-06
DE60024893T2 (de) 2006-07-06
SI1210113T1 (sl) 2006-08-31
DE60024893D1 (de) 2006-01-19
DK1410805T3 (da) 2006-04-18
NO20033715D0 (no) 2003-08-21
WO2001017551A2 (en) 2001-03-15
KR20030087081A (ko) 2003-11-12
ES2261243T3 (es) 2006-11-16
NO20033715L (no) 2002-04-30
KR20020027630A (ko) 2002-04-13
ATE321569T1 (de) 2006-04-15
US6936255B1 (en) 2005-08-30
CN1387443A (zh) 2002-12-25
NO20021116L (no) 2002-04-30
HUP0303215A3 (en) 2008-04-28
ZA200306402B (en) 2004-08-02
BR0014171A (pt) 2002-05-21
TW200408405A (en) 2004-06-01
HU228687B1 (en) 2013-05-28
CN100389824C (zh) 2008-05-28
ES2253636T3 (es) 2006-06-01
CA2443214C (en) 2006-03-21
CN1325117C (zh) 2007-07-11
CY1106090T1 (el) 2011-06-08
CA2384064A1 (en) 2001-03-15
IL148456A0 (en) 2002-09-12
GC0000201A (en) 2006-03-29
ATE312624T1 (de) 2005-12-15
NO332800B1 (no) 2013-01-14
CA2443214A1 (en) 2001-03-15
EP1769806A3 (en) 2007-10-24
EP1769806A2 (en) 2007-04-04
HK1048435B (en) 2007-01-05
MY142842A (en) 2011-01-14
NO2012016I1 (no) 2012-10-15
US20040126394A1 (en) 2004-07-01
HK1064958A1 (en) 2005-02-08
NZ527560A (en) 2004-12-24
US20060280756A1 (en) 2006-12-14
JP2003508495A (ja) 2003-03-04
EP1410805B1 (en) 2005-12-14
AU7775100A (en) 2001-04-10
AU766494B2 (en) 2003-10-16
DE60027029T2 (de) 2006-10-19
NO2012016I2 (no) 2012-10-08

Similar Documents

Publication Publication Date Title
CO5280045A1 (es) Nueva composicion
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
IL148844A0 (en) Methods related to immunostimulatory nucleic acid-induced interferon
WO2001051083A3 (en) Innate immunity-stimulating compositions of cpg and saponin and methods thereof
BR9908599A (pt) Composições combinadas de vacina
EP1618889B8 (en) Influenza Vaccine
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
IL164812A0 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
JP2003508495A5 (es)
UA88457C2 (ru) Иммуностимулирующая нуклеиновая кислота с улучшенной иммуностимулирующей эффективностью
PE20071098A1 (es) Composicion inmugenica que contiene como adyuvantes una saponina y un polisacarido
WO1999033868A3 (en) Human papillomavirus vaccine
AU4322996A (en) Variants of human papilloma virus antigens
MXPA02002483A (es) Vacuna contra vhb y vph.
MY110086A (en) Herpes simplex virus vaccines comrpising glycoprotein d and 3d-mpl
HUP0301180A2 (hu) Imidazokinolinaminok adjuvánsként való használata DNS vakcinálásban
AR042530A1 (es) Vacuna que comprende particulas viroides del virus papiloma humano 16 y 18
AR034312A1 (es) Composicion de vacuna que comprende al menos un antigeno del virus de la inmunodeficiencia humana (vih), kit de vacunacion que la comprende, uso de un antigeno de vph y vhs para la preparacion de la composicion de vacuna y procedimiento para la preparacion de dicha vacuna
ATE274919T1 (de) Feste dispergierende impfstoffe-zusammensetzung zur oralen verabreichung
PT777669E (pt) Utilizacao de succinato de 4-(2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-ciclopenteno-1-metanol como agente antiviral
DE60037327D1 (de) Neues verfahren zur herstellung von virus-ähnlichen partikeln des menschen-papillomavirus mit verbesserten eigenschaften
NZ516725A (en) Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
AR025203A1 (es) Nuevos genes de mixoma para modulacion inmunitaria
AR041249A2 (es) Una composicion de vacuna

Legal Events

Date Code Title Description
FC Application refused